Full Press Release Details
Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering
Taipei City, Taiwan, June 16, 2025 --- Jyong Biotech Ltd. (the "Company"), a science-driven biotechnology company based
in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in
the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the pricing
of its initial public offering (the "Offering") of 2,666,667 ordinary shares (the "Ordinary Shares") at a public
offering price of $7.50 per share. The Company expects to receive aggregate gross proceeds of approximately $20 million, before deducting
underwriting discounts and other offering expenses. The Ordinary Shares have been approved for listing on the Nasdaq Global Market and
are expected to commence trading on June 17, 2025 under the ticker symbol "MENS". The Offering is expected to close on June
18, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters an option
(the "Over-Allotment Option"), within 45 days from the date of the final prospectus, to purchase up to an additional
400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover the Over-Allotment Option, if any.
net proceeds from the Offering will be used for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new drug application
of MCS-2 (40%); (ii) funding earlier phase trials if the Company is unable to demonstrate comparability (25%); (iii) funding the Phase
II trial of PCP (10%); (iv) funding the Phase I clinical trial of IC (5%), and (v) general corporate purposes (20%).
Offering is being conducted on a firm commitment basis. Joseph Stone Capital, LLC is acting as sole underwriter for the Offering (the
"Underwriter"). Sichenzia Ross Ference Carmel LLP is acting as U.S. securities counsel to the Company, and VCL Law LLP is
acting as U.S. securities counsel to the Underwriter, in connection with the Offering.
registration statement on Form F-1 (File No. 333-277725) relating to the Offering, as amended, has been filed with the U.S. Securities
and Exchange Commission (the "SEC") and was declared effective by the SEC on June 16, 2025. The Offering is being made
only by means of a prospectus. Copies of the prospectus related to the Offering may be obtained, when available, from Joseph Stone Capital,
LLC by standard mail to Joseph Stone Capital, LLC, 585 Stewart Ave., Suite L60-C, Garden City, NY 11530, or via email at corporatefinance@josephstonecapital.com
or by telephone at +1 (888) 302-5548. In addition, a copy of the prospectus relating to the Offering, when available, can also be obtained
via the SEC's website at www.sec.gov.
you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about
the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer
to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.
in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated
new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the
U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities
of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization.
Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical
drug candidates, including its primary botanical drug candidate, MCS-2, another clinical-stage botanical drug candidate, and other preclinical-stage
botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs
and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: https://www.jyongbio.com/,
press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals,
strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical
facts. When the Company uses words such as "may, "will, "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation,
the Company's statements regarding the expected trading of its Ordinary Shares on the Nasdaq Global Market and the closing of the
Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements
are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and the completion
of the initial public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section
of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC,
which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements
to reflect events or circumstances that arise after the date hereof.
more information, please contact:
Investor Relations Inc.
Wang, Managing Partner